Pharmacytimes: Condition Center: Atrial Fibrillation http://www.pharmacytimes.com/condition-resources/afib/condition-rss Atrial Fibrillation en-us Sat, 28 Feb 2015 06:52:30 UTC Sat, 28 Feb 2015 06:52:30 UTC Cutting-Edge Heart Model Predicts Changes in the Heart That Can Lead to Atrial Fibrillation http://www.pharmacytimes.com/condition-resources/afib/Cutting-Edge-Heart-Model-Predicts-Changes-in-the-Heart-That-Can-Lead-to-Atrial-Fibrillation A paper from a pair of physicists may reveal significant new information about the causes of atrial fibrillation and help to make cardiac ablations a more effective treatment for the condition. Thu, 19 Feb 2015 03:17:00 UTC Better Prescribing Needed for Newer Atrial Fibrillation Agent http://www.pharmacytimes.com/condition-resources/afib/Better-Prescribing-Needed-for-Newer-Atrial-Fibrillation-Agent Prescribing methods for a newer atrial fibrillation agent require more monitoring to improve patient safety in community hospitals. Sat, 14 Feb 2015 09:00:00 UTC Anti-Clotting Agent Launches in United States http://www.pharmacytimes.com/condition-resources/afib/Anti-Clotting-Agent-Launches-in-United-States Daiichi Sankyo today announced the US launch of edoxaban, a once-daily anti-clotting agent indicated for reducing the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation. Mon, 09 Feb 2015 03:38:00 UTC Which Atrial Fibrillation Patients Are Most Likely to Misreport Symptoms? http://www.pharmacytimes.com/condition-resources/afib/Which-Atrial-Fibrillation-Patients-Are-Most-Likely-to-Misreport-Symptoms A primary goal of managing atrial fibrillation is relief of symptoms that include dizziness, fatigue, palpitations, shortness of breath, and chest pain. Yet, it is symptomless in up to one-third of patients. Fri, 30 Jan 2015 05:02:00 UTC Barriers to Anticoagulant Use in Atrial Fibrillation http://www.pharmacytimes.com/condition-resources/afib/Barriers-to-Anticoagulant-Use-in-Atrial-Fibrillation Use of anticoagulants in atrial fibrillation patients remains unacceptably low, with some estimates showing that only half of patients receive anticoagulants as indicated by current treatment guidelines. Mon, 26 Jan 2015 03:00:00 UTC FDA Approves Anti-Clotting Drug for Atrial Fibrillation http://www.pharmacytimes.com/condition-resources/afib/FDA-Approves-Anti-Clotting-Drug-for-Atrial-Fibrillation The FDA has approved Daiichi Sankyo’s anti-clotting drug, edoxaban (Savaysa), as a once-daily treatment to reduce the risk of stroke and systemic embolism in patients with non-valvular atrial fibrillation. Fri, 09 Jan 2015 02:56:43 UTC Can an Aspirin a Day Keep Post-Atrial Fibrillation Clots Away? http://www.pharmacytimes.com/condition-resources/afib/Can-an-Aspirin-a-Day-Keep-Post-Atrial-Fibrillation-Clots-Away Roughly 50 million Americans take daily low-dose aspirin for cardioprevention, as it is generally perceived as a safe, effective, and inexpensive OTC preventive medication for cardiovascular disease. For patients who have nonvalvular atrial fibrillation, many guidelines recommend aspirin as thromboprophylaxis among those who are not considered to be high risk. Wed, 07 Jan 2015 02:02:01 UTC Digoxin Raises Death Risk in Atrial Fibrillation Patients http://www.pharmacytimes.com/condition-resources/afib/Digoxin-Raises-Death-Risk-in-Atrial-Fibrillation-Patients Digoxin is associated with a 71% increased risk of death and a 63% higher risk of hospitalization among adults diagnosed with atrial fibrillation who have no evidence of heart failure. Mon, 24 Nov 2014 05:25:01 UTC Pradaxa Linked to Fewer Strokes in Atrial Fibrillation Than Warfarin http://www.pharmacytimes.com/condition-resources/afib/Pradaxa-Linked-to-Fewer-Strokes-in-Atrial-Fibrillation-Than-Warfarin- Two new analyses of more than 60,000 patients found dabigatran etexilate was linked to fewer major bleeds and strokes than warfarin. Sat, 22 Nov 2014 05:53:59 UTC Endurance Exercise Elevates Atrial Fibrillation Risk http://www.pharmacytimes.com/condition-resources/afib/Endurance-Exercise-Elevates-Atrial-Fibrillation-Risk Is moderation the key to all things, including exercise? Tue, 18 Nov 2014 01:53:01 UTC Bleeding Risk Face Off: Dabigatran Versus Warfarin http://www.pharmacytimes.com/news/Bleeding-Risk-Face-Off-Dabigatran-Versus-Warfarin- As new anticoagulants for atrial fibrillation enter the marketplace, health care professionals desire to understand how the drugs compare to the tried-and-true prototype, warfarin. Mon, 03 Nov 2014 07:05:15 UTC New Guidelines for Postoperative Atrial Fibrillation: Key Points for Pharmacists http://www.pharmacytimes.com/news/New-Guidelines-for-Postoperative-Atrial-Fibrillation-Key-Points-for-Pharmacists Updated guidelines for postoperative atrial fibrillation contain several pieces of information for pharmacists to help prevent medication errors. Tue, 14 Oct 2014 06:24:45 UTC Digoxin Carries More Than 200 Years of Controversy, Especially in Atrial Fibrillation http://www.pharmacytimes.com/condition-resources/afib/Digoxin-Carries-More-than-200-Years-of-Controversy-Especially-in-Atrial-Fibrillation Approximately 6.5 million Americans are prescribed digoxin, a cardiac glycoside with a long, fascinating history. Mon, 15 Sep 2014 12:25:01 UTC Atrial Fibrillation and Anticoagulation: Bleeds Happen, Antidotes Needed http://www.pharmacytimes.com/condition-resources/afib/Atrial-Fibrillation-and-Anticoagulation-Bleeds-Happen-Antidotes-Needed Several new anticoagulants have entered the US market in recent years, but research to find reversal agents for these drugs is ongoing. Tue, 26 Aug 2014 08:54:17 UTC Atrial Fibrillation Patients Prescribed Digoxin Are More Likely to Die http://www.pharmacytimes.com/condition-resources/afib/Atrial-Fibrillation-Patients-Prescribed-Digoxin-Are-More-Likely-to-Die Digoxin increases risk of death in patients with newly diagnosed atrial fibrillation. Thu, 14 Aug 2014 02:08:13 UTC Vitamin K Antagonists and Atrial Fibrillation: Time in Therapeutic Range http://www.pharmacytimes.com/condition-resources/afib/Vitamin-K-Antagonists-and-Atrial-Fibrillation-Time-in-Therapeutic-Range Researchers evaluated more than 2 decades of evidence on atrial fibrillation patients taking vitamin K antagonists. Mon, 28 Jul 2014 07:56:35 UTC Anticoagulation and Risk for Falls in the Atrial Fibrillation Patient http://www.pharmacytimes.com/condition-resources/afib/Anticoagulation-and-Risk-for-Falls-in-the-Atrial-Fibrillation-Patient Researchers evaluated the risk of cardiovascular outcomes in atrial fibrillation patients with a history of falls. Wed, 02 Jul 2014 07:04:43 UTC Atrial Fibrillation: The Growing Cost of Hospitalization http://www.pharmacytimes.com/condition-resources/afib/Atrial-Fibrillation-The-Growing-Cost-of-Hospitalization A recent investigation found a significant increase in hospitalization rates for patients with atrial fibrillation in the United States. Fri, 06 Jun 2014 08:48:40 UTC NSAIDs in the Elderly: Another Cautionary Result http://www.pharmacytimes.com/condition-resources/afib/NSAIDs-in-the-Elderly-Another-Cautionary-Result Current and recent users of nonsteroidal anti-inflammatory drugs were significantly more likely to develop atrial fibrillation, according to the results of a new study. Thu, 15 May 2014 01:43:42 UTC The New Atrial Fibrillation Guidelines: An In-Depth Guide http://www.pharmacytimes.com/condition-resources/afib/The-New-Atrial-Fibrillation-Guidelines-An-In-Depth-Guide New atrial fibrillation treatment guidelines from the American Heart Association and American College of Cardiology clarify the role of novel oral anticoagulants and rate/rhythm control medications. Tue, 22 Apr 2014 04:12:52 UTC